Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(10):723-732; doi:10.1093/jnci/95.10.723
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sviderskaya, E. V.
Right arrow Articles by Bennett, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sviderskaya, E. V.
Right arrow Articles by Bennett, D. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 10, 723-732, May 21, 2003
© 2003 Oxford University Press

ARTICLE

p16/Cyclin-Dependent Kinase Inhibitor 2A Deficiency in Human Melanocyte Senescence, Apoptosis, and Immortalization: Possible Implications for Melanoma Progression

Elena V. Sviderskaya, Vanessa C. Gray-Schopfer, Simon P. Hill, Nico P. Smit, Tracy J. Evans-Whipp, Jane Bond, Lucy Hill, Veronique Bataille, Gordon Peters, David Kipling, David Wynford-Thomas, Dorothy C. Bennett

Affiliations of authors: E. V. Sviderskaya, V. C. Gray-Schopfer, S. P. Hill, T. J. Evans-Whipp, L. Hill, D. C. Bennett, Department of Basic Medical Sciences, St. George’s Hospital Medical School, London, UK; N. P. Smit, Leiden University Medical Center, Department of Dermatology, Leiden, The Netherlands; J. Bond, D. Kipling, D. Wynford-Thomas, Department of Pathology, University of Wales College of Medicine, Cardiff, UK; V. Bataille, Twin Research and Genetic Epidemiology Unit, St. Thomas’ Hospital, London; G. Peters, Cancer Research UK London Institute, London.

Correspondence to: Dorothy C. Bennett, Ph.D., Department of Basic Medical Sciences, St. George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK (e-mail: dbennett{at}sghms.ac.uk).

Background: The melanoma susceptibility locus cyclin-dependent kinase inhibitor 2A encodes two unrelated cell growth inhibitors, p16 and alternative reading frame (ARF). In fibroblasts, both proteins are implicated in cellular senescence, a key barrier to tumor development. The p16 coding sequence is more often mutated in melanoma families than is the ARF sequence. To investigate the role of p16 in melanocytes, we assessed aspects of growth, apoptosis, and immortalization in melanocytes cultured from two melanoma patients, both of whom had two inactive p16 alleles but functional ARF. Methods: Growth and senescence were evaluated by cumulative population-doubling curves, and apoptosis by terminal deoxytransferase labeling. Expression of p53 and p21, which are associated with fibroblast senescence, was assessed by immunoblotting. Amphotropic retroviruses were used to transfer exogenous gene sequences into the melanocytes. Results: Both melanocyte cultures showed high rates of apoptosis, which were reduced when the cells were grown in the presence of keratinocyte feeder cells or human stem cell factor plus endothelin 1. With these growth factors, both cultures proliferated for 45–55 net population doublings, markedly longer than the maximum of 10 net population doublings of normal adult human melanocytes in similar media, indicating impaired senescence. One of the cultures developed chromosomal aberrations, with numerous dicentric chromosomes at senescence, consistent with telomere dysfunction. p53 and p21 levels were not elevated in senescent normal melanocytes but were elevated in senescent p16-deficient melanocytes. Interference with p53 function by transfer of human papillomavirus 16-E6 further extended the lifespan of p16-deficient melanocytes. Human telomerase reverse transcriptase was sufficient to immortalize both these cell strains but not normal melanocytes. Conclusion: Normal senescence in human melanocytes requires p16 activity. p53 contributes to a delayed form of senescence that requires telomere shortening, in p16-deficient melanocytes. These findings provide some basis for the role of p16 in melanoma susceptibility.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Ha, T. Ichikawa, M. Anver, R. Dickins, S. Lowe, N. E. Sharpless, P. Krimpenfort, R. A. DePinho, D. C. Bennett, E. V. Sviderskaya, et al.
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence
PNAS, June 26, 2007; 104(26): 10968 - 10973.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. W. Vance, S. Carreira, G. Brosch, and C. R. Goding
Tbx2 Is Overexpressed and Plays an Important Role in Maintaining Proliferation and Suppression of Senescence in Melanomas
Cancer Res., March 15, 2005; 65(6): 2260 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
K. Hardy, L. Mansfield, A. Mackay, S. Benvenuti, S. Ismail, P. Arora, M. J. O'Hare, and P. S. Jat
Transcriptional Networks and Cellular Senescence in Human Mammary Fibroblasts
Mol. Biol. Cell, February 1, 2005; 16(2): 943 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. Matheu, C. Pantoja, A. Efeyan, L. M. Criado, J. Martin-Caballero, J. M. Flores, P. Klatt, and M. Serrano
Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging
Genes & Dev., November 15, 2004; 18(22): 2736 - 2746.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.